Table 1.

Patient baseline characteristics

Cyclophosphamide (n = 27)No cyclophosphamide (n = 25)
Sex
 Female9 (33%)5 (20%)
 Male18 (67%)20 (80%)
 Mean age, y65.263.1
Site of primary
 Right5 (19%)4 (16%)
 Left9 (33%)12 (48%)
 Sigmoid/rectum10 (37%)9 (36%)
 Not identified3 (11%)0 (0%)
Site of metastases
 Liver19 (70%)14 (56%)
 Lung11 (41%)13 (52%)
 Peritoneum11 (41%)8 (32%)
WHO Performance status
 015 (56%)10 (40%)
 112 (44%)14 (56%)
 20 (0%)1 (4%)
Previous treatment
 Primary colectomy15 (56%)17 (68%)
 Capecitabine27 (100%)25 (100%)
 5-Fluorouracil24 (89%)24 (96%)
 Irinotecan11 (41%)11 (44%)
 Oxaliplatin9 (33%)9 (36%)
 Cetuximab3 (11%)0 (0%)
 Aflibercept2 (7%)1 (4%)